Jennison Associates
SUPN icon

Jennison Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Jennison Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,837
Closed -$589K – 699
2018
Q2 		$589K Sell
9,837
-9,490
-49% -$492K ﹤0.01% 614
2018
Q1 		$885K Buy
+19,327
New +$807K ﹤0.01% 567

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Jennison Associates's SUPN Position: Q3 2018 in Review

Jennison Associates sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 9,837 shares — an estimated $589K sold.

Jennison Associates first reported a position in SUPN in Q1 2018 and held it in 2 quarters. The position peaked at $885K in Q1 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Jennison Associates reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Jennison Associates sold 9,837 Supernus Pharmaceuticals shares in Q3 2018, an estimated $589K.
  • Jennison Associates first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Jennison Associates's Supernus Pharmaceuticals position peaked at $885K in Q1 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.